A panel of FDA advisers is meeting to discuss testing four drugs with potential to treat childhood cancers. Relatively few children are affected by cancer, making robust clinical trial design difficult. The FDA requires drugmakers to study their products in children if children are prone to the target disease, and new legislation taking effect next month will require those studies even earlier.

Full Story:

Related Summaries